|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: APCDD1 |
Gene summary for APCDD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | APCDD1 | Gene ID | 147495 |
| Gene name | APC down-regulated 1 | |
| Gene Alias | B7323 | |
| Cytomap | 18p11.22 | |
| Gene Type | protein-coding | GO ID | GO:0001942 | UniProtAcc | Q8J025 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 147495 | APCDD1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.26e-15 | 4.63e-01 | 0.0155 |
| 147495 | APCDD1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.17e-09 | 5.05e-01 | 0.0216 |
| 147495 | APCDD1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.58e-13 | 6.06e-01 | -0.1464 |
| 147495 | APCDD1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.57e-05 | 3.45e-01 | -0.059 |
| 147495 | APCDD1 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.17e-02 | 4.18e-01 | -0.0842 |
| 147495 | APCDD1 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.37e-59 | 1.89e+00 | 0.096 |
| 147495 | APCDD1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.65e-18 | 1.13e+00 | 0.0338 |
| 147495 | APCDD1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.56e-26 | 6.44e-01 | 0.0674 |
| 147495 | APCDD1 | HTA11_11156_2000001011 | Human | Colorectum | AD | 9.65e-07 | 8.33e-01 | 0.0397 |
| 147495 | APCDD1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.21e-39 | 1.03e+00 | 0.294 |
| 147495 | APCDD1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.14e-46 | 1.29e+00 | 0.3859 |
| 147495 | APCDD1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.51e-09 | 4.38e-01 | 0.2585 |
| 147495 | APCDD1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.97e-106 | 1.98e+00 | 0.3005 |
| 147495 | APCDD1 | F007 | Human | Colorectum | FAP | 7.74e-06 | 3.49e-01 | 0.1176 |
| 147495 | APCDD1 | A002-C-010 | Human | Colorectum | FAP | 6.99e-13 | 4.31e-01 | 0.242 |
| 147495 | APCDD1 | A001-C-207 | Human | Colorectum | FAP | 1.16e-14 | 5.44e-01 | 0.1278 |
| 147495 | APCDD1 | A015-C-203 | Human | Colorectum | FAP | 6.20e-20 | 7.45e-01 | -0.1294 |
| 147495 | APCDD1 | A015-C-204 | Human | Colorectum | FAP | 3.59e-05 | 3.20e-01 | -0.0228 |
| 147495 | APCDD1 | A002-C-201 | Human | Colorectum | FAP | 3.85e-03 | 2.22e-01 | 0.0324 |
| 147495 | APCDD1 | A002-C-203 | Human | Colorectum | FAP | 8.13e-03 | 1.93e-01 | 0.2786 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| GO:0008544 | Colorectum | AD | epidermis development | 87/3918 | 324/18723 | 5.99e-03 | 3.76e-02 | 87 |
| GO:00301112 | Colorectum | MSS | regulation of Wnt signaling pathway | 98/3467 | 328/18723 | 3.37e-07 | 1.36e-05 | 98 |
| GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
| GO:01987382 | Colorectum | MSS | cell-cell signaling by wnt | 124/3467 | 446/18723 | 7.83e-07 | 2.77e-05 | 124 |
| GO:0030178 | Colorectum | MSS | negative regulation of Wnt signaling pathway | 48/3467 | 170/18723 | 1.23e-03 | 1.18e-02 | 48 |
| GO:00160553 | Colorectum | FAP | Wnt signaling pathway | 104/2622 | 444/18723 | 4.92e-08 | 3.92e-06 | 104 |
| GO:01987383 | Colorectum | FAP | cell-cell signaling by wnt | 104/2622 | 446/18723 | 6.26e-08 | 4.54e-06 | 104 |
| GO:00301113 | Colorectum | FAP | regulation of Wnt signaling pathway | 81/2622 | 328/18723 | 1.44e-07 | 9.03e-06 | 81 |
| GO:0043588 | Colorectum | FAP | skin development | 58/2622 | 263/18723 | 2.44e-04 | 3.39e-03 | 58 |
| GO:00085441 | Colorectum | FAP | epidermis development | 66/2622 | 324/18723 | 9.63e-04 | 9.51e-03 | 66 |
| GO:00301781 | Colorectum | FAP | negative regulation of Wnt signaling pathway | 38/2622 | 170/18723 | 2.06e-03 | 1.70e-02 | 38 |
| GO:0022404 | Colorectum | FAP | molting cycle process | 21/2622 | 84/18723 | 5.10e-03 | 3.37e-02 | 21 |
| GO:0022405 | Colorectum | FAP | hair cycle process | 21/2622 | 84/18723 | 5.10e-03 | 3.37e-02 | 21 |
| GO:00160554 | Colorectum | CRC | Wnt signaling pathway | 88/2078 | 444/18723 | 3.91e-08 | 5.28e-06 | 88 |
| GO:01987384 | Colorectum | CRC | cell-cell signaling by wnt | 88/2078 | 446/18723 | 4.85e-08 | 6.04e-06 | 88 |
| GO:00301114 | Colorectum | CRC | regulation of Wnt signaling pathway | 68/2078 | 328/18723 | 2.41e-07 | 2.27e-05 | 68 |
| GO:00085442 | Colorectum | CRC | epidermis development | 57/2078 | 324/18723 | 2.88e-04 | 4.59e-03 | 57 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| APCDD1 | SNV | Missense_Mutation | rs746711951 | c.638N>A | p.Arg213Gln | p.R213Q | Q8J025 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| APCDD1 | SNV | Missense_Mutation | c.1127N>A | p.Ala376Glu | p.A376E | Q8J025 | protein_coding | tolerated(1) | benign(0.028) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| APCDD1 | SNV | Missense_Mutation | c.265N>C | p.Glu89Gln | p.E89Q | Q8J025 | protein_coding | deleterious(0.04) | possibly_damaging(0.747) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| APCDD1 | SNV | Missense_Mutation | c.165G>T | p.Met55Ile | p.M55I | Q8J025 | protein_coding | tolerated(0.14) | possibly_damaging(0.62) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| APCDD1 | insertion | In_Frame_Ins | novel | c.906_907insTCCACATCACACCTGAAATGTTTGCGTAGGTCTGTACTGTCAGGCAAA | p.Val302_Arg303insSerThrSerHisLeuLysCysLeuArgArgSerValLeuSerGlyLys | p.V302_R303insSTSHLKCLRRSVLSGK | Q8J025 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| APCDD1 | deletion | Frame_Shift_Del | novel | c.1515delN | p.Pro506LeufsTer62 | p.P506Lfs*62 | Q8J025 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| APCDD1 | SNV | Missense_Mutation | rs758081145 | c.1300N>T | p.Arg434Cys | p.R434C | Q8J025 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| APCDD1 | SNV | Missense_Mutation | rs374082304 | c.908N>A | p.Arg303His | p.R303H | Q8J025 | protein_coding | deleterious(0.01) | possibly_damaging(0.736) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| APCDD1 | SNV | Missense_Mutation | rs758870123 | c.932N>A | p.Arg311His | p.R311H | Q8J025 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| APCDD1 | SNV | Missense_Mutation | rs149564774 | c.120N>T | p.Glu40Asp | p.E40D | Q8J025 | protein_coding | tolerated(0.07) | benign(0.011) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |